JPRN-UMIN000024330未知2 期
A phase II study of combination chemotherapy of oral tegafur/uracil, leucovorin and bevacizumab for patients not appropriate for intensive therapy with unresectable or recurrent colorectal cancer - A phase II study of UFT/LV and bevacizumab treatment
Dept of Surgical Oncology Osaka City University Graduate School of Medicine0 个研究点目标入组 35 人开始时间: 2016年10月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with a past history of severe drug allergy 2)no other co-existing malignancy or malignancy within the last five years prior to enrollment other than non-melanoma skin cancer or in situ carcinoma of the cervix 3)patients were pregnant or lactating 4)Patients with psychiatric illness 5)Patients with severe co-morbidities (renal failure, liver dysfunction, uncontrolable diabetes mellitus and hypertension, heart failure) 6)Patients with massive ascites or hydrothorax 7)Patients with a symptomatic brain metastasis 8)Patients with abdominal surgery within 28days 9)Patients with perforated disease 10)Patients with thrombosis 11)Patiens with 3+ proteinurea
研究者
相似试验
已完成
2 期
A Phase II study of combination chemotherapy with TS-1 and Trastuzumab for patients with HER2 positive advanced or recurrent gastric cancer.advanced or recurrent gastric cancerJPRN-UMIN000008220Osaka medical center for cancer and cardiovascular diseases20
已完成
2 期
A phase II study of combination chemotherapy with carboplatin plus S-1 in advanced lung squamous cell carcinomaung cancerJPRN-UMIN000006983Hamamatsu University School of Medicine50
已完成
2 期
A phase II study of combination chemotherapy with carboplatin plus S-1 in advanced and recurrence non small cell lung cancernon-small-cell lung cancerJPRN-UMIN000010189ational Hospital Organization Osaka20
已完成
2 期
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
已完成
1 期
Phase I-II study of combination chemotherapy with Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancerClear cell or mucinous ovarian cancerJPRN-UMIN000005952Osaka university, faculty of medicine40